Correspondence 0001213900-23-053634 from Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc.
Date: June 30, 2023 · CIK: 0001860657 · Accession: 0001213900-23-053634
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272469
Letter
24 School Street, 2nd Floor
Boston, MA 02108
June 30, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua R. Gorsky
Re: Allarity Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-272469)
Request for Acceleration
Requested Date: July 5, 2023
Requested Time: 5:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-1, as amended, (File No. 333-272469) be accelerated so that the same will become effective at 5:30 p.m., Eastern Time, on July 5, 2023, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.
Very Truly Yours,
Allarity Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
24 School Street, 2nd Floor
Boston, MA 02108
June 30, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Joshua R. Gorsky
Re: Allarity Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-272469)
Request for Acceleration
Requested Date: July 5, 2023
Requested Time: 5:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned hereby respectfully requests that the effective date of its Registration Statement on Form S-1,
as amended, (File No. 333-272469) be accelerated so that the same will become effective at 5:30 p.m., Eastern Time, on July 5, 2023, or
as soon thereafter as is practicable.
If you have any questions regarding this request,
please contact our counsel Daniel B. Eng of Lewis Brisbois Bisgaard & Smith LLP at (415) 262-8508.
Very Truly Yours,
Allarity Therapeutics, Inc.
By:
/s/ James G. Cullem
Name:
James G. Cullem
Title:
Chief Executive Officer